| Literature DB >> 30364023 |
Paphon Sa-Ngasoongsong1, Siwadol Wongsak1, Chavarat Jarungvittayakon1, Kawee Limsamutpetch1, Thanaphot Channoom1, Viroj Kawinwonggowit1.
Abstract
BACKGROUND: Periprosthetic joint infection (PJI) remains challenging since a "gold standard" for diagnosis has not yet been established. This study aimed to evaluate the accuracy of synovial fluid procalcitonin (SF-PCT) and serum procalcitonin as a diagnostic biomarker for PJI and to compare its accuracy against standard methods.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30364023 PMCID: PMC6188588 DOI: 10.1155/2018/8351308
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Definition for periprosthetic joint infection by International Consensus Group.
| Periprosthetic joint infection (PJI) is present when one major criterion exists or when three of five minor criteria exist | |
| Major criteria | (1) Two positive periprosthetic cultures with phenotypically identical organisms |
| (2) A sinus tract communicating with the joint | |
| Minor criteria | (1) Elevated serum C-reactive protein AND erythrocyte sedimentation rate |
| (2) Elevated synovial fluid white blood cell (WBC) count OR ++change on leukocyte esterase test strip | |
| (3) Elevated synovial fluid polymorphonuclear neutrophil percentage | |
| (4) Positive histological analysis of periprosthetic tissue | |
| (5) A single positive culture | |
The threshold for the minor diagnostic criteria according to the International Consensus Group.
|
|
|
|
|---|---|---|
|
| Not helpful; no threshold was determined | 30 |
|
| 100 | 10 |
|
| 10,000 | 3,000 |
|
| 90 | 80 |
|
| + or ++ | Same as acute |
|
| >5 neutrophils/HPF in 5 HPFs (x400) | Same as acute |
PJI: periprosthetic joint infection; HPF: high power field.
Patient characteristics data.
|
|
|
|
| |
|---|---|---|---|---|
|
|
|
| ||
| Age, year◆ | 68 (65–74) | 70 (66–76) | 67 ± 5 | 0.098 |
| Female gender | 25 (78%) | 13 (65%) | 12 (100%) | 0.029 |
| BMI, kg/m2△ | 26.9 ± 4.0 | 26.3 ± 4.5 | 28.1 ± 3.0 | 0.229 |
| Hip : Knee❖ | 5 : 27 | 0 : 20 | 5 : 7 | 0.004 |
| Left : Right❖ | 14 : 18 | 10 : 10 | 4 : 8 | 0.471 |
| CCI◆ | 3 (2-4) | 3 (3-4) | 2.5 ± 1.0 | 0.083 |
| Systemic inflammatory disease | 2 (6%) | 1 (5%) | 1 (8%) | 1.000 |
| Receiving immunomodulating drugs | 2 (6%) | 1 (5%) | 1 (8%) | 1.000 |
| Body temperature (°C)◆ | 36.8 (36.5–37.3) | 37.4 ± 0.9 | 36.6 ± 0.2 | 0.010 |
| WBC count (cell/mm3)◆ | 6,620 (5,755–10,250) | 9,170 (1,700–28,100) | 6106 ± 1433 | 0.021 |
PJI: periprosthetic joint infection, BMI: body mass index, CCI: Charlson comorbidity index, and WBC: white blood cell; ◆: value presented as mean ± SD or mean (IQR) and calculated with Mann–Whitney U test; ◎: value presented as number of cases (percentage) and calculated with Fisher exact test or Chi-square test as appropriate; △: value presented with mean ± standard deviation and calculated with unpaired t-test; ❖: value presented as the proportion of cases with that condition and calculated with Fisher exact test; significant p value with p < 0.05.
Relevant clinical and laboratory findings for PJI definition.
|
|
|
| |
|---|---|---|---|
|
| 0 (0%) | 0 (0%) | 1.00 |
|
| 13 (65%) | 0 (0%) | <0.001 |
|
| 14 (70%) | 0 (0%) | <0.001 |
|
| |||
|
| 81 ± 27 | 18.5 (12.5–36.5) | <0.001 |
|
| 149 ± 98 | 2.9 ± 2.5 | <0.001 |
|
| 0.33 (0.08–2.79) | 0.04 (0.03–0.06) | <0.001 |
|
| n/a | 0.04 (0.02–0.06) | n/a |
|
| 0.33 (0.08–2.79) | 0.04 ± 0.04 | 0.001 |
|
| |||
|
| 78,920 (3,420–335,400) | 1350 ± 827 | <0.001 |
|
| 90.8 ± 6.2 | 54.9 ± 17.2 | <0.001 |
|
| 0.16 (0.12–0.26) | 0.00 (0.00–0.00) | <0.001 |
|
| n/a | 0.00 0.00 | n/a |
|
| 0.16 (0.12–0.26) | 0.00 (0.00–0.06) | 0.004 |
◎: value presented as number of cases (percentage), △: value presented as mean ± standard deviation, ▽: value presented as median (interquartile range), and n/a: not available.
Microbiological findings of culture-diagnosed PJI among 14 episodes.
|
|
|
|---|---|
| Gram positive | |
| | 1 (7%) |
| CNS | 1 (7%) |
| Streptococci | 7 (50) |
| Gram positive | |
| | 3 (21%) |
| | 1 (7%) |
| Othera | 1 (7%) |
CNS: coagulative negative staphylococcus; a: Propionibacterium spp.
Diagnostic accuracy of PJI diagnosis using serum or synovial fluid procalcitonin.
|
|
|
|
|
| |
|---|---|---|---|---|---|
|
| |||||
| 0.1 | 65.0 (40.8–84.6) | 91.7 (61.5–99.8) | 0.78 (0.60–0.91) | 7.80 (1.16–52.35) | 0.38 (0.21–0.71) |
| 0.3 | 50.0 (27.2–72.8) | 100.0 (73.5–100.0) | 0.75 (0.57–0.89) | n/a | 0.47 (0.29–0.76) |
| 0.5 | 40.0 (19.1–64.0) | 100.0 (73.5–100.0) | 0.70 (0.51–0.85) | n/a | 0.60 (0.42–0.86) |
|
| |||||
| 0.08 | 90.0 (68.3–98.8) | 83.3 (51.6–97.9) | 0.87 (0.70–0.96) | 5.40 (1.51–19.30) | 0.12 (0.03–0.46) |
| 0.12 | 80.0 (56.3–94.3) | 91.7 (61.5–99.8) | 0.86 (0.69–0.96) | 9.60 (1.45–63.50) | 0.22 (0.09–0.53) |
| 0.16 | 55.0 (31.5–76.9) | 91.7 (61.5–99.8) | 0.73 (0.55–0.87) | 6.60 (0.97–44.93) | 0.49 (0.29–0.82) |
AUC: area under curve, LR+: positive likelihood ratio, LR-: negative likelihood ratio, and PCT: procalcitonin.
Figure 1Receiver-operating characteristic (ROC) curves comparing ability between serum and synovial fluid PCT to detect periprosthetic joint infection (PJI) before revision arthroplasty.